Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730509 | 0.82 | ALDH1A1 (0.41) | ARALDH1A1CYP2A6MAOBMAOA | |
| SCHEMBL29728269 | 0.82 | ALDH1A1 (0.41) | ARALDH1A1CYP2A6MAOBMAOA | |
| SCHEMBL1003862 | 0.78 | ALDH1A1 (0.46) | ARALDH1A1CYP2A6MAOBMAOA | |
| SCHEMBL4060179 | 0.77 | AR (0.42) | ARALDH1A1CYP2A6MAOBMAOA | |
| SCHEMBL11110756 | 0.77 | RAB9A (0.38) | ALDH1A1CYP2A6MEN1HPGDKMT2A | |
| SCHEMBL28618637 | 0.77 | ALDH1A1 (0.35) | ALDH1A1CYP2A6MEN1HPGDALOX15 | |
| SCHEMBL18615409 | 0.77 | AR (0.52) | AR | |
| SCHEMBL1343170 | 0.76 | MAOB (0.48) | ALDH1A1ABCG2MAOBMAOATSHR | |
| SCHEMBL277588 | 0.76 | TSHR (0.52) | ARALDH1A1CYP2A6TSHRPKM | |
| SCHEMBL30361887 | 0.76 | TSHR (0.52) | ARALDH1A1CYP2A6TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-08-26 | — | — | US | disclosed |
| US-20250250267-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-07 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-119798258-A | Nitrogen-containing bridge heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798257-A | Nitrogen-containing bridge heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798256-A | Nitrogen-containing bridge heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| CN-115572252-B | Isoindolinone inhibitors of MDM2-P53 interaction with anticancer activity | 阿斯泰克斯治疗有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5432190-A | Antimycotic and aromatase inhibitory activities | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-07-11 | — | — | US | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| US-5407952-A | Azole derivatives, pharmaceutical compositions containing the same, and method for treating mycosis and estrogen-dependent diseases | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-04-18 | — | — | US | disclosed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0005607-B1 | XANTHONE AND THIOXANTHONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KEFALAS A/S (DK) | 1983-10-26 | — | — | EP | disclosed |
| US-4309429-A | NEUROLEPTIC, ANTIEMETIC | KEFALAS A/S (DK) | 1982-01-05 | — | — | US | disclosed |
| US-4285956-A | NEUROLEPTIC AND ANTICHOLENERGIC AGENTS; PSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA; ANTIEMETIC AGENTS | KEFALAS A/S (DK) | 1981-08-25 | — | — | US | disclosed |
| US-4275209-A | NEUROLEPTIC AND ANTIEMETIC ACTIVITY FOR TREATMENT OF PSYCHOLOGICAL DISORDERS | KEFALAS A/S (DK) | 1981-06-23 | — | — | US | disclosed |
| EP-0005607-A1 | Xanthone and thioxanthone derivatives, their preparation and pharmaceutical compositions containing them | KEFALAS A/S (DK) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | AR 900/4885ALDH1A1 1361/4885CYP2A6 2566/4885 |
| US-20250250267-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | CFB, F11, CFH | AR 4441/4885ALDH1A1 3027/4885CYP2A6 1069/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | AR 2358/4885ALDH1A1 3064/4885CYP2A6 158/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | AR 1962/4885ALDH1A1 996/4885CYP2A6 704/4885 |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | PTGIS, PTGS1, PTGES | AR 1213/4885ALDH1A1 676/4885CYP2A6 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.